In view of the remarkable genetic diversity demonstrated by KIR and HLA class I genes and their functional cooperation in immunity, it is reasonable to postulate that different KIR-HLA combinations could be associated with differential capabilities of NK cells and of certain T-cell subsets to kill tumor cells. We previously reported a significant increased frequency of more inhibitory KIR genotypes in leukemic patients. 5 It is likely that a dominance of inhibitory over activating signals may influence the NK and/or T-cell activity to lyse leukemic cells. To address this issue, we studied the incidence of KIR genes in combination with their known HLA ligands in 31 patients with chronic lymphoid leukemia (CLL), 48 patients with myeloid leukemia and 148 healthy unrelated individuals from the same ethnic group.
HLA-B and -C typing was performed by polymerase chain reaction (PCR)-sequence-specific oligonucleotides (SSO) method using Lifecodes HLA-SSO typing kit. HLA-B and -C allotypes of patients were then grouped according to their KIR-binding motifs (HLA-Bw4 from -Bw6 and HLA-C1 from -C2) and compared to that of the controls. We could not find a significance difference in the frequency of HLA-B groups between myeloid leukemic patients and controls. We only noticed a trend towards higher frequency of HLA-Bw4/Bw6 heterozygotes in patients with CLL (64.5%) relative to the controls (46.6%) (odds ratio ¼ 2.40; 95% CI ¼ 1.06-5.46, P ¼ 0.070). We further investigated the distribution of the HLA-C1 and -C2 epitopes among patients and controls, but no significant associations were found.
As our interest was mainly focused on those KIR genes that interact with HLA-class I alleles, we analyzed the frequencies of only the inhibitory KIR2DL1, À2DL2, À2DL3, À3DL1 and activating KIR2DS1, À2DS2, À3DS1 in association with their HLA-class I ligands. The PCR-sequence specific primer technique was performed for the amplification of these KIRs. 5 Firstly, we observed that the combination of KIR3DL1 and the HLABw4 ligand was significantly associated with CLL (77.4 versus 54.7% in the control group) suggesting an additive effect between these two genes in the development of CLL (odds ratio ¼ 2.84; 95% CI ¼ 1.15-6.99, P ¼ 0.026). Furthermore, it has been shown that the activating KIR3DS1 segregates as an allele of the inhibitory KIR3DL1, because of their negative linkage disequilibrium and high-sequence homology. We examined therefore the association of HLA-Bw4 with CLL in the context of KIR3DL1 and KIR3DS1 subtypes ( Table 1 ). The percentage of KIR3DL1 homozygotes (3DL1/3DL1) that were positive for the HLA-Bw4 ligand was strongly increased in patients with CLL compared to the controls. When we looked in more detail, most of the patients who were homozygous for KIR3DL1 had only one copy of HLA-Bw4 (Bw4/Bw6) (48.4 versus 23% in the control group, P ¼ 0.004) (data not shown). On the other hand, a significantly higher number of controls who were homozygous for KIR3DL1 lacked the HLA-Bw4 ligand (HLA-Bw6/Bw6). Our previous study showed that the HLA class I expression on most leukemic cells was downregulated, but was mostly restricted to HLA-A and HLA-B belonging to the Bw6 group. 6 As Bw4, but not Bw6, protects target cells from NK cell attack, the inhibitory interaction mediated by KIR3DL1 and Bw4 in CLL described in this study is in agreement with our previous observation. 6 Next, we investigated the frequencies of these KIR genes in combination with their HLA class I ligands in patients with myeloid leukemia. We analyzed patients with acute myeloid leukemia (n ¼ 29) and chronic myeloid leukemia (CML) (n ¼ 19) together as one group, because recent clinical studies in HLAmismatched HSCT showed that patients with myeloid leukemia are susceptible to NK cell killing. 2 In contrast to the lymphoid leukemic patients, we observed an increased frequency of KIR2DL2 and KIR2DS2 in combination with their HLA-C1 ligand in patients with myeloid leukemia (52.1%) compared to controls (31.7%) (odds ratio 2.33, 95% CI 1.20-4.54, P ¼ 0.011). As KIR2DL3 segregates as an allele of the inhibitory KIR2DL2, we also compared the frequency of KIR2DL2 and KIR2DL3 homo-and heterozygotes (Table 2 ). In the presence of HLA-C1, a significant higher frequency of KIR2DL2/2DL3 heterozygotes was observed in the myeloid leukemic patients, whereas the presence of KIR2DL3/2DL3 homozygotes was increased in the control group. Consequently, this will result in a stronger inhibition, because it has been shown that KIR2DL2 binds HLA-C1 with greater affinity than does KIR2DL3. Consistent with our finding, a recent study showed that the presence of inhibitory KIR2DL2/2DL3 in association with their putative ligands was also increased in melanoma patients compared to healthy individuals. 7 Finally, we also found that 27.1% of patients who were heterozygous for KIR2DL2/2DL3 were also heterozygous for HLA-C1/C2 (versus 12.8% in the control group, P ¼ 0.020) (data not shown).
In conclusion, the results obtained in this study showed that the frequency of particular inhibitory KIRs in association with their putative HLA class I ligands was significantly increased in leukemic patients compared to the controls. This finding supports our previous observation 5 and hypothesis that leukemic cells may have evolved an escape mechanism from immune surveillance based on the dominance of inhibitory over activating KIR signals. It is obvious that the potential strong inhibition mediated by KIR3DL1-Bw4 interactions in CLL, along with that conferred by KIR2DL2-Cw1 in myeloid leukemia which was most pronounced in CML, both decrease immune activation that we propose is linked to these two different subtypes of leukemia. In addition to the involvement of KIR-HLA in susceptibility to leukemia, it has been demonstrated that additional mechanisms of leukemic escape from NK cell immunity exist such as downregulation of natural cytotoxicity receptors; leukemic cells may lack the expression of ligands for activating receptors or secrete high amounts of MICA/B, which block the NKG2D receptor on NK cells.
8 Table 1 Frequencies of KIR3DL1, KIR3DS1 and HLA-B combinations among controls and patients with CLL 
